Comparative characterization of two monoclonal antibodies targeting canine PD-1
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F24%3A00080192" target="_blank" >RIV/00209805:_____/24:00080192 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1382576/full" target="_blank" >https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1382576/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2024.1382576" target="_blank" >10.3389/fimmu.2024.1382576</a>
Alternative languages
Result language
angličtina
Original language name
Comparative characterization of two monoclonal antibodies targeting canine PD-1
Original language description
Monoclonal antibodies targeting immune checkpoints have revolutionized oncology. Yet, the effectiveness of these treatments varies significantly among patients, and they are associated with unexpected adverse events, including hyperprogression. The murine research model used in drug development fails to recapitulate both the functional human immune system and the population heterogeneity. Hence, a novel model is urgently needed to study the consequences of immune checkpoint blockade. Dogs appear to be uniquely suited for this role. Approximately 1 in 4 companion dogs dies from cancer, yet no antibodies are commercially available for use in veterinary oncology. Here we characterize two novel antibodies that bind canine PD-1 with sub-nanomolar affinity as measured by SPR. Both antibodies block the clinically crucial PD-1/PD-L1 interaction in a competitive ELISA assay. Additionally, the antibodies were tested with a broad range of assays including Western Blot, ELISA, flow cytometry, immunofluorescence and immunohistochemistry. The antibodies appear to bind two distinct epitopes as predicted by molecular modeling and peptide phage display. Our study provides new tools for canine oncology research and a potential veterinary therapeutic.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/GA22-02940S" target="_blank" >GA22-02940S: Regulation of IFN-γ signaling pathway with HSP90 inhibitors</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in immunology
ISSN
1664-3224
e-ISSN
1664-3224
Volume of the periodical
15
Issue of the periodical within the volume
May 2024
Country of publishing house
CH - SWITZERLAND
Number of pages
16
Pages from-to
1382576
UT code for WoS article
001228698300001
EID of the result in the Scopus database
2-s2.0-85193840434